Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 21 | 2025 | 380 | 6.150 |
Why?
|
| Tuberculosis | 23 | 2025 | 520 | 5.770 |
Why?
|
| Tuberculosis, Pulmonary | 9 | 2024 | 216 | 3.070 |
Why?
|
| DNA Methylation | 5 | 2025 | 1009 | 1.910 |
Why?
|
| Immune Tolerance | 4 | 2024 | 144 | 1.850 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2024 | 153 | 1.400 |
Why?
|
| Epigenesis, Genetic | 5 | 2025 | 678 | 1.360 |
Why?
|
| Adaptive Immunity | 3 | 2021 | 90 | 1.330 |
Why?
|
| Feces | 4 | 2024 | 727 | 1.190 |
Why?
|
| Sputum | 7 | 2024 | 105 | 1.170 |
Why?
|
| BCG Vaccine | 5 | 2023 | 109 | 1.160 |
Why?
|
| HIV Infections | 11 | 2025 | 1890 | 0.940 |
Why?
|
| Citric Acid Cycle | 1 | 2024 | 47 | 0.920 |
Why?
|
| Antitubercular Agents | 8 | 2024 | 245 | 0.840 |
Why?
|
| Interferon-gamma Release Tests | 3 | 2025 | 82 | 0.820 |
Why?
|
| Lipopolysaccharides | 1 | 2024 | 293 | 0.820 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 30 | 0.810 |
Why?
|
| Fetal Blood | 1 | 2023 | 176 | 0.800 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2024 | 504 | 0.740 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 106 | 0.660 |
Why?
|
| Sensitivity and Specificity | 11 | 2024 | 2052 | 0.650 |
Why?
|
| Bacteriological Techniques | 2 | 2016 | 87 | 0.630 |
Why?
|
| Leukocytes | 1 | 2020 | 210 | 0.620 |
Why?
|
| Communicable Diseases | 1 | 2021 | 160 | 0.620 |
Why?
|
| Ascaris lumbricoides | 1 | 2018 | 19 | 0.600 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 18 | 0.600 |
Why?
|
| Schistosomiasis | 1 | 2018 | 50 | 0.580 |
Why?
|
| Immunity, Innate | 2 | 2021 | 373 | 0.560 |
Why?
|
| Ascariasis | 1 | 2018 | 74 | 0.560 |
Why?
|
| Th1 Cells | 1 | 2018 | 153 | 0.560 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 472 | 0.550 |
Why?
|
| Transcriptome | 2 | 2022 | 952 | 0.540 |
Why?
|
| Schistosoma | 1 | 2016 | 10 | 0.520 |
Why?
|
| Immunologic Factors | 2 | 2021 | 174 | 0.510 |
Why?
|
| Humans | 49 | 2025 | 124936 | 0.490 |
Why?
|
| Antigens, Helminth | 1 | 2016 | 190 | 0.470 |
Why?
|
| Population Surveillance | 2 | 2022 | 388 | 0.460 |
Why?
|
| Macrophages | 1 | 2016 | 620 | 0.390 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2523 | 0.370 |
Why?
|
| Signal Transduction | 2 | 2021 | 4537 | 0.370 |
Why?
|
| Immunologic Memory | 2 | 2021 | 189 | 0.320 |
Why?
|
| Child | 16 | 2024 | 24318 | 0.300 |
Why?
|
| DNA, Bacterial | 3 | 2024 | 478 | 0.280 |
Why?
|
| Interleukin-4 | 2 | 2018 | 140 | 0.270 |
Why?
|
| Animals | 9 | 2024 | 34248 | 0.270 |
Why?
|
| South Africa | 2 | 2023 | 99 | 0.260 |
Why?
|
| Cytokines | 3 | 2022 | 1286 | 0.250 |
Why?
|
| Inflammation | 2 | 2022 | 1442 | 0.230 |
Why?
|
| Succinic Acid | 1 | 2024 | 14 | 0.230 |
Why?
|
| Succinates | 1 | 2024 | 20 | 0.230 |
Why?
|
| Child, Preschool | 8 | 2024 | 13972 | 0.230 |
Why?
|
| Interferon-gamma | 2 | 2018 | 506 | 0.230 |
Why?
|
| Biomarkers | 2 | 2024 | 3080 | 0.230 |
Why?
|
| T-Lymphocytes | 2 | 2025 | 1718 | 0.230 |
Why?
|
| Everolimus | 1 | 2024 | 49 | 0.230 |
Why?
|
| Gene Silencing | 1 | 2025 | 236 | 0.220 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 364 | 0.220 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2025 | 138 | 0.210 |
Why?
|
| Adult | 14 | 2024 | 29587 | 0.210 |
Why?
|
| Adolescent | 10 | 2024 | 19303 | 0.210 |
Why?
|
| Ultraviolet Therapy | 1 | 2022 | 2 | 0.200 |
Why?
|
| Immunity | 1 | 2023 | 192 | 0.200 |
Why?
|
| CRISPR-Cas Systems | 1 | 2025 | 253 | 0.200 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 20 | 0.200 |
Why?
|
| Isosporiasis | 1 | 2021 | 3 | 0.190 |
Why?
|
| Guinea Pigs | 1 | 2022 | 167 | 0.190 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 292 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 43 | 0.190 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 64 | 0.190 |
Why?
|
| Young Adult | 5 | 2024 | 9035 | 0.190 |
Why?
|
| Cryptococcus | 1 | 2021 | 3 | 0.180 |
Why?
|
| Herpesvirus 8, Human | 1 | 2021 | 47 | 0.180 |
Why?
|
| Systems Biology | 1 | 2021 | 57 | 0.180 |
Why?
|
| Vaccination | 2 | 2023 | 961 | 0.180 |
Why?
|
| Cryptococcosis | 1 | 2021 | 42 | 0.180 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2021 | 70 | 0.180 |
Why?
|
| Allergy and Immunology | 1 | 2021 | 26 | 0.180 |
Why?
|
| Kava | 1 | 2020 | 7 | 0.180 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 69 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2023 | 882 | 0.180 |
Why?
|
| Cellular Senescence | 1 | 2022 | 161 | 0.180 |
Why?
|
| History, 19th Century | 1 | 2021 | 116 | 0.170 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2021 | 119 | 0.170 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2021 | 260 | 0.170 |
Why?
|
| Eosinophilia | 1 | 2021 | 101 | 0.170 |
Why?
|
| Sarcoma, Kaposi | 1 | 2021 | 119 | 0.170 |
Why?
|
| Herpesviridae Infections | 1 | 2021 | 142 | 0.170 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 42 | 0.170 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 316 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 243 | 0.160 |
Why?
|
| Transcription Factors | 2 | 2021 | 2594 | 0.160 |
Why?
|
| Diarrhea | 1 | 2021 | 317 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 225 | 0.160 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 73 | 0.160 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 383 | 0.160 |
Why?
|
| History, 20th Century | 1 | 2021 | 381 | 0.160 |
Why?
|
| RNA | 1 | 2022 | 571 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 253 | 0.160 |
Why?
|
| Health Personnel | 1 | 2023 | 501 | 0.150 |
Why?
|
| Gene Expression | 1 | 2023 | 1561 | 0.150 |
Why?
|
| Immunization | 1 | 2020 | 307 | 0.150 |
Why?
|
| Colony Count, Microbial | 1 | 2018 | 89 | 0.150 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 68 | 0.150 |
Why?
|
| Limit of Detection | 1 | 2018 | 63 | 0.150 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2018 | 33 | 0.150 |
Why?
|
| Autoantibodies | 1 | 2021 | 436 | 0.140 |
Why?
|
| Mycobacterium chelonae | 1 | 2017 | 6 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2024 | 6145 | 0.140 |
Why?
|
| Wound Healing | 1 | 2021 | 460 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2020 | 318 | 0.140 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2017 | 46 | 0.140 |
Why?
|
| Viral Vaccines | 1 | 2020 | 337 | 0.130 |
Why?
|
| Age Factors | 1 | 2023 | 2817 | 0.130 |
Why?
|
| Helminths | 1 | 2017 | 48 | 0.130 |
Why?
|
| Tanzania | 3 | 2024 | 68 | 0.130 |
Why?
|
| Calibration | 1 | 2016 | 89 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2023 | 3294 | 0.130 |
Why?
|
| CD56 Antigen | 1 | 2016 | 26 | 0.130 |
Why?
|
| Phagosomes | 1 | 2016 | 36 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2021 | 676 | 0.130 |
Why?
|
| Hookworm Infections | 1 | 2017 | 125 | 0.130 |
Why?
|
| CD3 Complex | 1 | 2016 | 91 | 0.130 |
Why?
|
| Reference Standards | 1 | 2016 | 236 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 173 | 0.120 |
Why?
|
| Male | 12 | 2024 | 61388 | 0.120 |
Why?
|
| Coinfection | 1 | 2017 | 170 | 0.120 |
Why?
|
| Immunophenotyping | 1 | 2016 | 329 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2021 | 4806 | 0.120 |
Why?
|
| Age of Onset | 1 | 2016 | 591 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 2016 | 174 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 327 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 605 | 0.120 |
Why?
|
| Latent Tuberculosis | 1 | 2016 | 73 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 356 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 371 | 0.110 |
Why?
|
| Female | 11 | 2024 | 66672 | 0.110 |
Why?
|
| Skin | 1 | 2017 | 518 | 0.110 |
Why?
|
| Lysosomes | 1 | 2016 | 237 | 0.110 |
Why?
|
| Mozambique | 2 | 2024 | 20 | 0.110 |
Why?
|
| Antigens, Bacterial | 1 | 2016 | 314 | 0.110 |
Why?
|
| Risk Factors | 2 | 2020 | 10270 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2016 | 797 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 397 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2886 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1105 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3054 | 0.100 |
Why?
|
| Pathology, Molecular | 2 | 2022 | 58 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2164 | 0.090 |
Why?
|
| Uganda | 2 | 2024 | 75 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2309 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1696 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4398 | 0.090 |
Why?
|
| Middle Aged | 6 | 2024 | 26888 | 0.080 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2007 | 18 | 0.070 |
Why?
|
| Infant | 5 | 2024 | 12455 | 0.070 |
Why?
|
| Mice | 1 | 2024 | 17646 | 0.070 |
Why?
|
| Prognosis | 1 | 2016 | 4624 | 0.070 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2007 | 53 | 0.070 |
Why?
|
| Aged | 2 | 2023 | 19831 | 0.070 |
Why?
|
| Time Factors | 1 | 2016 | 6326 | 0.060 |
Why?
|
| Geriatric Psychiatry | 1 | 2006 | 11 | 0.060 |
Why?
|
| Foreign Medical Graduates | 1 | 2006 | 12 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2427 | 0.060 |
Why?
|
| Family Practice | 1 | 2006 | 91 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2025 | 49 | 0.060 |
Why?
|
| Jurkat Cells | 1 | 2025 | 92 | 0.060 |
Why?
|
| Tuberculin Test | 1 | 2025 | 123 | 0.060 |
Why?
|
| HIV-1 | 1 | 2007 | 464 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 275 | 0.050 |
Why?
|
| Gene Editing | 1 | 2025 | 187 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2025 | 737 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 64 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2006 | 454 | 0.050 |
Why?
|
| Kenya | 1 | 2022 | 52 | 0.050 |
Why?
|
| Phototherapy | 1 | 2022 | 34 | 0.050 |
Why?
|
| Isospora | 1 | 2021 | 3 | 0.050 |
Why?
|
| HIV | 1 | 2023 | 180 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 42 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2017 | 267 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 139 | 0.050 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2022 | 63 | 0.050 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 13 | 0.050 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2021 | 20 | 0.040 |
Why?
|
| Isoniazid | 1 | 2021 | 61 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2022 | 12374 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 248 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2020 | 114 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 182 | 0.040 |
Why?
|
| Rituximab | 1 | 2021 | 158 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2021 | 136 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2021 | 290 | 0.040 |
Why?
|
| Cell Line | 1 | 2025 | 2757 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1094 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2006 | 769 | 0.040 |
Why?
|
| United States | 3 | 2022 | 10899 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 353 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1356 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 265 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2021 | 266 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2019 | 79 | 0.040 |
Why?
|
| Syndrome | 1 | 2021 | 1120 | 0.040 |
Why?
|
| Metabolomics | 1 | 2021 | 423 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1169 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2017 | 53 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 231 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1608 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2017 | 121 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2021 | 752 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1883 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2006 | 1176 | 0.030 |
Why?
|
| Phenotype | 1 | 2025 | 4259 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 680 | 0.030 |
Why?
|
| Rural Population | 1 | 2017 | 257 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2017 | 314 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1234 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1898 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1501 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1497 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2023 | 16284 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2006 | 175 | 0.010 |
Why?
|
| Data Collection | 1 | 2006 | 381 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8191 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2006 | 997 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 3721 | 0.010 |
Why?
|